Drugmakers are in a race to develop vaccines and drugs to treat respiratory diseases caused by respiratory syncytial virus and COVID-19, resulting in increased demand for clinical testing of the products. The contract research organisation now expects its annual revenue to be 55 million pounds ($68.8 million), compared with 53 million pounds it previously expected.